Tumores Gastrintestinais
#ASCO22 – Estudo randomizado | Fluorouracil, leucovorina, oxaliplatina e irinotecano com panitumumabe vs. fluorouracil, leucovorina e oxaliplatina com panitumumabe para pacientes com câncer colorretal metastático tipo RAS/BRAF agressivo.
14 Jun, 2022 | 12:47h#ADA2022 – Estudo de coorte retrospectiva | Associação entre cirurgia bariátrica e risco de câncer e mortalidade em adultos com obesidade.
13 Jun, 2022 | 14:58hAssociation of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity – JAMA (gratuito por tempo limitado)
Editorial: Bariatric Surgery and Cancer Risk – JAMA (gratuito por tempo limitado)
Comunicado de imprensa: Weight loss with bariatric surgery cuts the risk of developing cancer and death from cancer – Cleveland Clinic
Comentários no Twitter
In this study, among adults with #obesity, #bariatricsurgery compared with no surgery was associated with a significantly lower incidence of obesity-associated #cancer and cancer-related mortality. https://t.co/x2gz3RUdra
— JAMA (@JAMA_current) June 3, 2022
Retrospective cohort presented at the @AmDiabetesAssn: incidence rate of 3.0 events vs 4.6 events per 1,000 person-years, resp, & a 32% reduced risk for developing obesity-related cancer following weight loss via surgery. @ClevelandClinic
https://t.co/6jLDmhgJbR @JAMA_current
— Karl Nadolsky (@DrKarlNadolsky) June 4, 2022
#ASCO2022 – Estudo randomizado | Análise do DNA circulante de tumor como orientação para terapia adjuvante no câncer de cólon estágio II.
13 Jun, 2022 | 14:56hCirculating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: DNA shed from colon cancers into bloodstream successfully guides chemotherapy after surgery – Helps clarify the benefit of chemotherapy in stage II cancers – Johns Hopkins Medicine
Comentário: ctDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers – Cancer Network
Comentário no Twitter
DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 pic.twitter.com/gvHMnGWbyE
— NEJM (@NEJM) June 4, 2022
#ASCO22 – Estudo de braço único fase 2 | Bloqueio PD-1 no câncer retal localmente avançado com deficiência do reparo de incompatibilidade.
13 Jun, 2022 | 14:39hPD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Diretriz de consenso | Papel atual da imunoterapia nos cânceres gástrico, esofágico e de junção gastroesofágica.
13 Jun, 2022 | 14:05hRevisão | Integração da biologia genômica nas estratégias terapêuticas para metástase peritoneal de câncer gástrico.
13 Jun, 2022 | 13:43hM-A | Radioterapia neoadjuvante de curta duração seguida de quimioterapia consolidada antes de cirurgia para tratar câncer retal localmente avançado.
13 Jun, 2022 | 13:40hEstudo randomizado | Durvalumabe com gencitabina e cisplatina no câncer avançado de trato biliar.
6 Jun, 2022 | 11:16hDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer – NEJM Evidence
Comentário no Twitter
Durvalumab, with gemcitabine plus cisplatin, increased median overall survival, 12.8 months versus 11.5 months, in patients with previously untreated unresectable, recurrent or metastatic biliary tract cancer. https://t.co/SaeUxfGfWd#OncTwitter #MedTwitter #Cholangiocarcinoma pic.twitter.com/NZeVljWnyu
— NEJM Evidence (@NEJMEvidence) June 1, 2022